Precision oncology startup 4baseCare has raised Rs 90 crore in the first close of its Series B funding round. The round is co-led by investors Ashish Kacholia and Lashit Sanghvi, with participation from existing investor Yali Capital.
The latest funding marks a major milestone for the company, which is building population-relevant clinico-genomic intelligence to improve cancer diagnosis and treatment outcomes. The capital will be used to expand its hospital-linked genomics lab network across India and several international markets, while accelerating the development of its AI-powered clinical decision support tools.
4baseCare had previously raised Rs 50 crore in a Series A round led by Yali Capital, with participation from Infosys, underscoring continued investor confidence in its long-term vision.
Understanding 4baseCare’s Mission in Precision Oncology
Addressing a Critical Gap in Cancer Care
Cancer treatment is increasingly moving toward precision medicine, where therapies are tailored to a patient’s genetic profile. However, most global cancer research and genomic datasets are heavily skewed toward Western populations, making them less effective for patients in emerging markets.
4baseCare was founded to address this gap by building population-relevant genomic datasets that reflect the genetic diversity of patients in regions such as India, Southeast Asia, and Latin America.
By combining clinical data, genomic insights, and real-world outcomes, the company aims to enable more accurate diagnosis and personalized treatment decisions for cancer patients.
What Makes 4baseCare’s Approach Different
Population-Relevant Clinico-Genomic Intelligence
Unlike traditional oncology platforms that rely on global datasets, 4baseCare focuses on generating and analyzing data that is specific to local populations. This approach helps oncologists better understand how different cancers behave across diverse genetic backgrounds.
The company integrates genomic sequencing with clinical context, creating a more complete picture of each patient’s condition and potential treatment pathways.
Hospital-Linked Genomics Lab Network
4baseCare operates a network of genomics laboratories that are closely linked with hospitals and oncology centers. This model allows for faster turnaround times, better coordination with clinicians, and improved integration of genomic insights into routine cancer care.
The planned expansion of this lab network will significantly increase access to advanced genomic testing in regions where such services are still limited.
How the Rs 90 Crore Funding Will Be Used
Expanding the Genomics Lab Network Globally
A significant portion of the funding will be allocated to expanding 4baseCare’s hospital-linked genomics labs across multiple geographies. These include India, the Middle East, Southeast Asia, Latin America, and Central Asia.
By establishing a strong presence in these regions, the company aims to make precision oncology more accessible to patients who are currently underserved by existing healthcare infrastructure.
Strengthening Clinical Partnerships
The expansion strategy also includes deeper collaborations with hospitals, cancer centers, and oncologists. These partnerships are critical to ensuring that genomic insights are seamlessly integrated into clinical workflows.
By working closely with clinicians, 4baseCare aims to improve adoption and real-world impact of precision oncology solutions.
Focus on AI-Driven Clinical Decision Support
Accelerating Product Development
Beyond physical infrastructure, 4baseCare will invest heavily in advancing its AI-driven clinical decision support solutions. These tools are designed to help oncologists interpret complex genomic data and translate it into actionable treatment recommendations.
The company plans to enhance its analytics capabilities, improve data models, and expand its real-world outcomes-linked datasets.
OncoTwin Insights and Its Role in Cancer Care
One of 4baseCare’s flagship platforms, OncoTwin Insights, plays a central role in this strategy. The solution uses AI to analyze large volumes of clinico-genomic data and match patients with similar profiles and outcomes.
This allows oncologists to gain insights into how comparable patients have responded to specific treatments, enabling more informed and personalized clinical decisions.
Why Investors Are Backing 4baseCare
Strong Conviction in Precision Oncology
Investors see precision oncology as one of the most promising areas in healthcare, with the potential to significantly improve survival rates and quality of life for cancer patients.
4baseCare’s focus on population-relevant data gives it a strong differentiation in a crowded global market, particularly in emerging economies.
Proven Execution and Growing Impact
The company’s ability to scale its lab network, build robust datasets, and develop clinically relevant AI tools has helped it gain credibility among both investors and healthcare providers.
The participation of existing investor Yali Capital in the Series B round signals continued confidence in the company’s execution and long-term potential.
The Bigger Picture: Precision Oncology in Emerging Markets
Rising Cancer Burden and Limited Access
Cancer incidence is rising rapidly across developing regions, driven by aging populations, lifestyle changes, and environmental factors. Yet access to advanced diagnostic and treatment tools remains uneven.
Precision oncology solutions like those developed by 4baseCare have the potential to bridge this gap by bringing cutting-edge science to regions that need it most.
Data as the Foundation of Better Outcomes
High-quality, diverse datasets are critical to advancing cancer research and improving treatment protocols. By building outcomes-linked clinico-genomic intelligence at scale, 4baseCare is contributing valuable data that can shape future oncology practices.
This approach not only benefits individual patients but also strengthens the broader healthcare ecosystem.
What Lies Ahead for 4baseCare
With fresh capital from prominent investors, 4baseCare is entering a new phase of growth. The company will focus on expanding its geographic footprint, deepening its AI capabilities, and strengthening partnerships with hospitals and clinicians.
As its datasets grow and its tools become more sophisticated, 4baseCare is well-positioned to play a leading role in the global precision oncology landscape, particularly across emerging markets.
Final Thoughts
4baseCare’s Rs 90 crore Series B funding round highlights growing investor interest in healthcare startups that combine genomics, AI, and real-world clinical data. By focusing on population-relevant precision oncology, the company is addressing a critical unmet need in cancer care.
If executed successfully, 4baseCare’s expansion and technology-driven approach could significantly improve how cancer is diagnosed and treated for millions of patients worldwide.
